AbbVie Inc
NYSE:ABBV

  • LAST PRICE
    193.8700
  • TODAY'S CHANGE (%)
    -1.5800 (-0.8084%)
  • Bid / Lots
    193.8500/ 1
  • Ask / Lots
    193.9000/ 1
  • Open / Previous Close
    195.1000 / 195.4500
  • Day Range
    193.0450
    195.6400
  • 52 Week Range
    135.8500
    199.9500
  • Volume
    3,175,223

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Pharmaceuticals - Diversified Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
ABBV
AbbVie Inc
345.2B
64.9x
-6.05%
MRK
Merck & Co Inc
279.3B
20.4x
-43.23%
NVS
Novartis AG
250.3B
23.2x
-5.59%
AZN
AstraZeneca PLC
243.4B
37.6x
+17.52%
RHHBY
Roche Holding AG
251.4B
19.5x
+3.28%
SNY
Sanofi SA
140.4B
29.9x
+4.55%
As of 2024-10-04

Company Information

AbbVie Inc. is a diversified research-based biopharmaceutical company engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Diffuse large B-cell lymphoma, and others. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders, and Alzheimer’s disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers, and others. It offers NX-13 for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). It also offers CEL383 for the treatment of inflammatory bowel disease.

Contact Information

Headquarters
1 N Waukegan RdNORTH CHICAGO, IL, United States 60064
Phone
847-932-7900
Fax
302-655-5049

Executives

Executive Chairman of the Board
Richard Gonzalez
Chief Executive Officer, Director
Robert Michael
Chief Financial Officer, Executive Vice President
Scott Reents
Chief Human Resource Officer, Executive Vice President
Timothy Richmond
Executive Vice President - Research & Development, Chief Scientific Officer
Roopal Thakkar

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$345.2B
Revenue (TTM)
$55.0B
Shares Outstanding
1.8B
Dividend Yield
3.20%
Annual Dividend Rate
6.2000 USD
Ex-Dividend Date
10-15-24
Pay Date
11-15-24
Beta
0.62
EPS
$2.99
Book Value
$5.87
P/E Ratio
64.9x
Price/Sales (TTM)
6.3
Price/Cash Flow (TTM)
24.9x
Operating Margin
22.31%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.